Clincosm LogoSign in Get a demo

Application of Antiosteoporosis Therapy in Osteolysis

Sponsor
Henan Cancer Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05617846
Collaborator
(none)
100
Enrollment
1
Location
117.1
Anticipated Duration (Months)
0.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To report the postoperative complications and limb function of patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis therapy in Henan Cancer Hospital in the next 10 years.

Condition or Disease Intervention/Treatment Phase
  • Other: Anti-osteoporosis therapy

Detailed Description

A total of 100 patients with osteolysis after surgery for bone tumors of the four extremities who received anti-osteoporosis treatment in Henan Cancer Hospital in the next 10 years were reported. The basic information, treatment methods, postoperative complications and limb function of these patients were collected.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
A Multicenter, Real-world Prospective Observational Study of Antiosteoporosis Therapy in Osteolysis After Limb Salvage Surgery for Malignant Tumors of Extremities
Anticipated Study Start Date :
Feb 28, 2023
Anticipated Primary Completion Date :
Nov 30, 2032
Anticipated Study Completion Date :
Nov 30, 2032

Arms and Interventions

Arm Intervention/Treatment
Receive anti-osteoporosis treatment

Bone healing, limb function, and complications in patients with osteolysis after surgery for bone tumors of the extremities who received anti-osteoporosis treatment in Henan Cancer Hospital.

Other: Anti-osteoporosis therapy
Bone healing, limb function, and complications of postoperative osteolysis in patients with bone tumors of the extremities treated with anti-osteoporosis therapy.

Outcome Measures

Primary Outcome Measures

  1. Complications [Collected from the beginning of treatment to 24 months after treatment.]

    The incidence of complications after anti-osteoporosis treatment was collected and the severity of complications was evaluated according to CTCAE5.0.

  2. Limb function [Collected from the beginning of treatment to 24 months after treatment.]

    Limb function was assessed using the Musculoskeletal Oncology Society (MSTS) scoring scale for seven items, namely movement, pain, stability, deformity, strength, functional activity, and emotional receptiveness. The highest possible score is 35, with 5 points allocated to each project.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Men and women of all ages are welcome. Pathologically confirmed in our hospital as a subtype of malignant tumor. He received limb salvage treatment for malignant bone tumor of extremities in our hospital.

She was diagnosed with osteolysis and received anti-osteoporosis treatment.

Exclusion Criteria:

Not applicable.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Bone and Soft Tissue ,Henan Cancer Hospital Zhengzhou Henan China

Sponsors and Collaborators

  • Henan Cancer Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wang Jiaqiang, associate chief physician, Henan Cancer Hospital
ClinicalTrials.gov Identifier:
NCT05617846
Other Study ID Numbers:
  • ZZUSC-19
First Posted:
Nov 16, 2022
Last Update Posted:
Jan 13, 2023
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Osteolysis

Study Results

No Results Posted as of Jan 13, 2023